ABL 506
Alternative Names: ABL506Latest Information Update: 13 Sep 2023
At a glance
- Originator ABL Bio; Handok Inc
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 13 Sep 2023 Discontinued for Solid tumours in South Korea (unspecified route) (Handok Inc pipeline, September 2023).